Answers are grounded in this paper and cite their sources.
Background of this guidelineRapidly progressive glomerulonephritis (RPGN) is defined in Japan as ''a syndrome that progresses rapidly within a few weeks or months to renal failure and is accompanied by urinary findings of nephritis.''The clinical concept of RPGN includes various renal diseases that cause renal function to deteriorate over a subacute course.Necrotizing crescentic glomerulonephritis is often observed in histopathological findings.In 2002, a joint committee formed by JSN and a research group on progressive renal disorders from the specific disease program of the Ministry of Health, Labour, and Welfare released Japan's first ''Clinical Guidelines for Rapidly Progressive Glomerulonephritis.''These landmark guidelines were based on the results of research conducted overseas and a national survey on RPGN and took the particular characteristics of Japan into consideration.The RPGN guidelines were divided into diagnostic guidelines for early discovery and guidelines for making definitive diagnoses.RPGN was categorized into either a myeloperoxidase (MPO-ANCA) or proteinase-3 antineutrophil cytoplasmic (PR3-ANCA) type based on ANCA-related vasculitis.Furthermore, a practical therapeutic algorithm was created for MPO-ANCA types that took into consideration factors such as clinical severity, age, and presence of dialysis.Treatment guidelines for anti-GBM antibody RPGN were also presented.These guidelines were widely used in Japan and contributed greatly to improving RPGN prognosis.These guidelines were revised 9 years later, in 2011, and published as ''Clinical Guidelines for Rapidly Progressive Glomerulonephritis-2nd edition.''This edition took into account medical advances that had occurred since 2002, and eGFR, not serum creatinine level, was adopted for diagnosing RPGN.Moreover, MPO-ANCA RPGN and PR3-ANCA RPGN were combined under ANCA-positive RPGN.The new edition also included concise statements for treatments and dealing with complications.Since then, marked progress has been made in RPGN research both in Japan and overseas.Globally, kidney disease improving global outcomes (KDIGO) released In 2011, the Research for Progressive Kidney Diseases of Ministry of Health and Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) established the collaborative clinical guidelines committee, which published JSN and MHLW Clinical Practice Guidelines for RPGN 2014 in Nihon Jinzo Gakkai Shi.2015; 57(1):139-232.This is the English version of that report, which was uploaded on JSN website on July 27, 2015.
No takes yet. Share an insight, caveat, or question.
Arimura et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: